CYPRE’S 3D in Vitro Platform Advances New Insights into the Tumor Microenvironment, Drives Data in 30 Days for Clients

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #3Dtumormodels–Cypre positions to deliver in vitro animal-alternatives to the biopharma drug discovery industry with the recent passing of the FDA Modernization Act. Historically drug testing requires animal models for efficacy and toxicity assessment but the Modernization Act ushers in a new path for in vitro…